Market Cap 22.51B
Revenue (ttm) 13.01B
Net Income (ttm) 746.00M
EPS (ttm) N/A
PE Ratio 17.06
Forward PE 15.33
Profit Margin 5.73%
Debt to Equity Ratio 0.58
Volume 497,700
Avg Vol 710,162
Day's Range N/A - N/A
Shares Out 82.90M
Stochastic %K 69%
Beta 1.00
Analysts Strong Sell
Price Target $302.24

Company Profile

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 336-584-5171
Fax: 336-436-1569
Address:
531 South Spring Street, Burlington, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 4 at 3:40 AM
$LH RSI: 74.10, MACD: 3.4942 Vol: 7.62, MA20: 264.71, MA50: 261.57 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
SuperGreenToday
SuperGreenToday Feb. 3 at 5:58 PM
$LH Share Price: $272.90 Contract Selected: Aug 21, 2026 $270 Calls Buy Zone: $18.70 – $23.10 Target Zone: $34.74 – $42.46 Potential Upside: 75% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
0 ¡ Reply
Ro_Patel
Ro_Patel Feb. 2 at 9:37 PM
In 2026, the big advances may come from companies that can make the most of AI. Goldman Sachs expects AI spending to decelerate from the previous year while company adoption increases, “causing rotations among the largest US tech stocks that create two-way risk for the aggregate index.” Goldman identified some of the trend’s greatest potential beneficiaries. The report analyzed Russell 1000 index stocks and excluded those that “did not mention AI in the context of productivity or efficiency on 2Q or 3Q earnings calls.” Goldman based their findings on each company’s labor costs alongside payroll exposure to AI automation. The report highlights companies across several sectors that are using AI to protect margins or boost earnings through automation. $BAC $IBM $EPAM $AMZN $LH
0 ¡ Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 3:17 PM
$LH Share Price: $266.64 Contract Selected: Aug 21, 2026 $280 Calls Buy Zone: $12.07 – $14.91 Target Zone: $21.73 – $26.56 Potential Upside: 70% ROI Time to Expiration: 208 Days | Updates via https://fxcapta.com/stockinfo/
0 ¡ Reply
SuperGreenToday
SuperGreenToday Jan. 13 at 12:38 AM
$LH Share Price: $250.29 Contract Selected: Aug 21, 2026 $240 Calls Buy Zone: $23.46 – $28.98 Target Zone: $44.25 – $54.08 Potential Upside: 78% ROI Time to Expiration: 220 Days | Updates via https://fxcapta.com/stockinfo/
0 ¡ Reply
iTrade_Price
iTrade_Price Jan. 12 at 2:08 PM
$LH LH
0 ¡ Reply
topstockalerts
topstockalerts Jan. 9 at 8:47 PM
U.S. clinical laboratories are appealing to Congress to prevent looming Medicare cuts of up to 15% that could affect Labcorp, Quest Diagnostics, and cancer-testing specialists like Guardant Health, Exact Sciences, and Natera. Starting in February, under current law, labs must report the rates that private insurers paid for tests in 2019. Medicare will then adjust its own payments to those levels in 2027. The American Clinical Laboratory Association warns that sustained cuts of this magnitude could limit patient access to life-saving diagnostics and reduce investment in next-generation clinical testing, including genomic tests used for diagnosing cancer patients and sick infants. Medicare’s approach to lab rates has been controversial: it originally surveyed commercial rates in 2016, cutting payments by up to 10% annually from 2018–2020, resulting in $4 billion in reductions—four times what Congress had projected. $LH $DGX $GH $EXAS
0 ¡ Reply
prismmarketview
prismmarketview Jan. 9 at 2:13 PM
NAMSA has acquired select U.S. assets of Labcorp’s (NYSE: $LH), Early Development medical device testing business—including biocompatibility, microbiological, analytical testing, and preclinical research—expanding its end‑to‑end MedTech services while allowing Labcorp to sharpen its focus on preclinical drug development and chemical testing. https://prismmarketview.com/namsa-expands-medtech-services-with-acquisition-of-labcorps-medical-device-testing-assets/
0 ¡ Reply
iTrade_Price
iTrade_Price Jan. 6 at 2:14 PM
$LH - will keep adding on weakness toward that UTL.
0 ¡ Reply
ZacksResearch
ZacksResearch Jan. 6 at 1:13 PM
$LH poised for growth despite macro headwinds! 🚀 In the past year, Labcorp rallied 10.1%, supported by strategic partnerships and acquisitions fueling its expansion in high-growth areas like oncology and neurology. Plus, with a market cap of $20.86B and a 7% earnings yield, it's outpacing its industry counterpart's 4.1%. Discover the full growth strategy here 👉 https://www.zacks.com/stock/news/2812340/should-labcorp-stock-stay-in-your-portfolio-right-now?cid=sm-stocktwits-2-2812340-body-27447&ADID=SYND_STOCKTWITS_TWEET_2_2812340_BODY_27447
0 ¡ Reply
Latest News on LH
Labcorp Declares Quarterly Dividend

Jan 14, 2026, 6:50 AM EST - 20 days ago

Labcorp Declares Quarterly Dividend


Labcorp Appoints Victor Bulto to Board of Directors

Nov 24, 2025, 8:30 AM EST - 2 months ago

Labcorp Appoints Victor Bulto to Board of Directors


Labcorp Holdings Inc. (LH) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 12:31 PM EDT - 3 months ago

Labcorp Holdings Inc. (LH) Q3 2025 Earnings Call Transcript


Labcorp Announces 2025 Third Quarter Results

Oct 28, 2025, 6:50 AM EDT - 3 months ago

Labcorp Announces 2025 Third Quarter Results


Labcorp Holdings Inc. (LH) Q2 2025 Earnings Call Transcript

Jul 24, 2025, 2:38 PM EDT - 6 months ago

Labcorp Holdings Inc. (LH) Q2 2025 Earnings Call Transcript


Why Is Testing Giant Labcorp Stock Surging On Thursday?

Jul 24, 2025, 12:27 PM EDT - 6 months ago

Why Is Testing Giant Labcorp Stock Surging On Thursday?


Labcorp Announces 2025 Second Quarter Results

Jul 24, 2025, 6:50 AM EDT - 6 months ago

Labcorp Announces 2025 Second Quarter Results


Labcorp to Webcast Its Annual Meeting of Shareholders May 15

May 8, 2025, 4:15 PM EDT - 9 months ago

Labcorp to Webcast Its Annual Meeting of Shareholders May 15


Labcorp Holdings Inc. (LH) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:21 PM EDT - 10 months ago

Labcorp Holdings Inc. (LH) Q1 2025 Earnings Call Transcript


Labcorp beats quarterly profit estimate on diagnostic test demand

Apr 29, 2025, 6:56 AM EDT - 10 months ago

Labcorp beats quarterly profit estimate on diagnostic test demand


Labcorp Announces 2025 First Quarter Results

Apr 29, 2025, 6:50 AM EDT - 10 months ago

Labcorp Announces 2025 First Quarter Results


Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 3:42 PM EST - 1 year ago

Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript


OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 4 at 3:40 AM
$LH RSI: 74.10, MACD: 3.4942 Vol: 7.62, MA20: 264.71, MA50: 261.57 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
SuperGreenToday
SuperGreenToday Feb. 3 at 5:58 PM
$LH Share Price: $272.90 Contract Selected: Aug 21, 2026 $270 Calls Buy Zone: $18.70 – $23.10 Target Zone: $34.74 – $42.46 Potential Upside: 75% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
0 ¡ Reply
Ro_Patel
Ro_Patel Feb. 2 at 9:37 PM
In 2026, the big advances may come from companies that can make the most of AI. Goldman Sachs expects AI spending to decelerate from the previous year while company adoption increases, “causing rotations among the largest US tech stocks that create two-way risk for the aggregate index.” Goldman identified some of the trend’s greatest potential beneficiaries. The report analyzed Russell 1000 index stocks and excluded those that “did not mention AI in the context of productivity or efficiency on 2Q or 3Q earnings calls.” Goldman based their findings on each company’s labor costs alongside payroll exposure to AI automation. The report highlights companies across several sectors that are using AI to protect margins or boost earnings through automation. $BAC $IBM $EPAM $AMZN $LH
0 ¡ Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 3:17 PM
$LH Share Price: $266.64 Contract Selected: Aug 21, 2026 $280 Calls Buy Zone: $12.07 – $14.91 Target Zone: $21.73 – $26.56 Potential Upside: 70% ROI Time to Expiration: 208 Days | Updates via https://fxcapta.com/stockinfo/
0 ¡ Reply
SuperGreenToday
SuperGreenToday Jan. 13 at 12:38 AM
$LH Share Price: $250.29 Contract Selected: Aug 21, 2026 $240 Calls Buy Zone: $23.46 – $28.98 Target Zone: $44.25 – $54.08 Potential Upside: 78% ROI Time to Expiration: 220 Days | Updates via https://fxcapta.com/stockinfo/
0 ¡ Reply
iTrade_Price
iTrade_Price Jan. 12 at 2:08 PM
$LH LH
0 ¡ Reply
topstockalerts
topstockalerts Jan. 9 at 8:47 PM
U.S. clinical laboratories are appealing to Congress to prevent looming Medicare cuts of up to 15% that could affect Labcorp, Quest Diagnostics, and cancer-testing specialists like Guardant Health, Exact Sciences, and Natera. Starting in February, under current law, labs must report the rates that private insurers paid for tests in 2019. Medicare will then adjust its own payments to those levels in 2027. The American Clinical Laboratory Association warns that sustained cuts of this magnitude could limit patient access to life-saving diagnostics and reduce investment in next-generation clinical testing, including genomic tests used for diagnosing cancer patients and sick infants. Medicare’s approach to lab rates has been controversial: it originally surveyed commercial rates in 2016, cutting payments by up to 10% annually from 2018–2020, resulting in $4 billion in reductions—four times what Congress had projected. $LH $DGX $GH $EXAS
0 ¡ Reply
prismmarketview
prismmarketview Jan. 9 at 2:13 PM
NAMSA has acquired select U.S. assets of Labcorp’s (NYSE: $LH), Early Development medical device testing business—including biocompatibility, microbiological, analytical testing, and preclinical research—expanding its end‑to‑end MedTech services while allowing Labcorp to sharpen its focus on preclinical drug development and chemical testing. https://prismmarketview.com/namsa-expands-medtech-services-with-acquisition-of-labcorps-medical-device-testing-assets/
0 ¡ Reply
iTrade_Price
iTrade_Price Jan. 6 at 2:14 PM
$LH - will keep adding on weakness toward that UTL.
0 ¡ Reply
ZacksResearch
ZacksResearch Jan. 6 at 1:13 PM
$LH poised for growth despite macro headwinds! 🚀 In the past year, Labcorp rallied 10.1%, supported by strategic partnerships and acquisitions fueling its expansion in high-growth areas like oncology and neurology. Plus, with a market cap of $20.86B and a 7% earnings yield, it's outpacing its industry counterpart's 4.1%. Discover the full growth strategy here 👉 https://www.zacks.com/stock/news/2812340/should-labcorp-stock-stay-in-your-portfolio-right-now?cid=sm-stocktwits-2-2812340-body-27447&ADID=SYND_STOCKTWITS_TWEET_2_2812340_BODY_27447
0 ¡ Reply
ZacksResearch
ZacksResearch Jan. 6 at 12:13 PM
$LH’s growth story isn’t one-sided — upside and real risks are on the table ⚠️ Growth bets in specialty testing and acquisitions are supporting LH’s outlook, but macro pressures and currency headwinds remain meaningful risks investors can’t ignore. Full risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2812340/should-labcorp-stock-stay-in-your-portfolio-right-now?cid=sm-stocktwits-2-2812340-teaser-27439&ADID=SYND_STOCKTWITS_TWEET_2_2812340_TEASER_27439
0 ¡ Reply
dontfeedthebashers
dontfeedthebashers Dec. 30 at 7:58 PM
0 ¡ Reply
ZacksResearch
ZacksResearch Dec. 22 at 1:57 PM
$HOLX vs. $LH — Which MedTech stock should you bet on? 🤔 Labcorp’s strategic partnerships and innovation in high-growth areas give it an edge, with analysts targeting a 19.3% upside. Meanwhile, Hologic's strength in diagnostics and breast health, along with M&A contributions, continue to support its performance. Find out which stock has the better outlook here 👉 https://www.zacks.com/stock/news/2807138/holx-vs-lh-which-medtech-stock-is-the-stronger-investment-now?cid=sm-stocktwits-2-2807138-body-25762&ADID=SYND_STOCKTWITS_TWEET_2_2807138_BODY_25762
0 ¡ Reply
ZacksResearch
ZacksResearch Dec. 22 at 12:02 PM
$HOLX vs. $LH — only one can be the stronger MedTech play right now 👀 This head-to-head breaks down which of these two MedTech names stacks up better as an investment right now, cutting straight to the strengths that matter most for investors. See which stock comes out on top 👉 https://www.zacks.com/stock/news/2807138/holx-vs-lh-which-medtech-stock-is-the-stronger-investment-now?cid=sm-stocktwits-2-2807138-teaser-25719&ADID=SYND_STOCKTWITS_TWEET_2_2807138_TEASER_25719
0 ¡ Reply
PEDO_Trump_LLC
PEDO_Trump_LLC Dec. 17 at 4:06 PM
$LH thought we'd be aiming at that $275 gap but, not yet
0 ¡ Reply
lauren_cooper88
lauren_cooper88 Dec. 12 at 5:50 PM
$LH Mainz Biomed has the perfect microcap mechanics, 1.00–1.06 day range on ~122k mid-day volume means the book is thin, give it a 400–500k day and the stair to 1.10–1.12 then 1.15–1.20 is wide open with UK ~44,000 CRC cases backdrop
0 ¡ Reply
BillionerOfKing
BillionerOfKing Dec. 3 at 1:36 AM
$LH Current Stock Price: $265.99 Contracts to trade: $270 LH Dec 19 2025 Call Entry: $2.90 Exit: $3.77 ROI: 30% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 ¡ Reply
ZacksResearch
ZacksResearch Dec. 2 at 1:10 PM
$LH outperforms the industry — but is it a hold or buy? 🤔 Despite a Zacks Rank #3, Labcorp's strategic expansions in oncology and genetic testing are noteworthy alongside a 16.8% rally over the past year, outpacing the industry's 9.4% growth. Yet, macroeconomic challenges and currency headwinds loom. Discover the full investment case here 👉 https://www.zacks.com/stock/news/2798098/should-you-continue-to-hold-lh-stock-in-your-portfolio?cid=sm-stocktwits-2-2798098-body-22983&ADID=SYND_STOCKTWITS_TWEET_2_2798098_BODY_22983
0 ¡ Reply
ZacksResearch
ZacksResearch Dec. 2 at 11:57 AM
Is $LH still worth holding here? ⚠️ When the headline itself is asking if you should “continue to hold,” that’s a clear signal this name is at an inflection point that investors can’t ignore. The full breakdown on whether LH still earns a spot in your portfolio 👉 https://www.zacks.com/stock/news/2798098/should-you-continue-to-hold-lh-stock-in-your-portfolio?cid=sm-stocktwits-2-2798098-teaser-22957&ADID=SYND_STOCKTWITS_TWEET_2_2798098_TEASER_22957
0 ¡ Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Nov. 24 at 2:04 PM
$LH RSI: 57.69, MACD: -2.3687 Vol: 7.63, MA20: 259.45, MA50: 271.74 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
ZacksResearch
ZacksResearch Nov. 21 at 2:12 PM
$LH makes waves with innovative Plasma Detect tech! 🌊 📈 Featured in Nature Medicine and Clinical Cancer Research, this tech aids in predicting long-term survival and tracking early disease progression in diffuse pleural mesothelioma treatment. 🔬 Enhanced detection capabilities in post-surgery scenarios, especially for head and neck cancer. Discover how this could shape LH’s future prospects 👉 https://www.zacks.com/stock/news/2794023/lh-shares-gain-following-publication-of-new-plasma-detect-mrd-data?cid=sm-stocktwits-2-2794023-body-21987&ADID=SYND_STOCKTWITS_TWEET_2_2794023_BODY_21987
0 ¡ Reply
ZacksResearch
ZacksResearch Nov. 21 at 1:12 PM
Big move brewing for $LH? New studies are putting Plasma Detect in the spotlight, showing its potential in tracking MRD and improving post-surgery cancer detection — and the shares are already edging higher on the news. Full breakdown here 👉 https://www.zacks.com/stock/news/2794023/lh-shares-gain-following-publication-of-new-plasma-detect-mrd-data?cid=sm-stocktwits-2-2794023-teaser-21986&ADID=SYND_STOCKTWITS_TWEET_2_2794023_TEASER_21986
0 ¡ Reply